Targets › CD46
5 programs from 3 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.
Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. (UniProt, P15529)
Open in Phaseline: the race on CD46, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kyntra Bio | FG-3246 anti-CD46 antibody-drug conjugate | CD46 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Mar 2028 |
| Robert Flavell, MD, PhD | Zirconium Zr 89-DFO-YS5 anti-CD46 radiopharmaceutical tracer (Zr-89 labeled) | CD46 | Phase 1 | Multiple Myeloma | Jan 2027 |
| Robert Flavell, MD, PhD | 89Zr-DFO-YS5 anti-CD46 antibody labeled with zirconium-89 for PET imaging | CD46 | Phase 1 | Prostate Cancer | Jul 2027 |
| Rahul Aggarwal | FOR46 anti-CD46 antibody-drug conjugate | CD46 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Jul 2027 |
| Robert Flavell, MD, PhD | YS5 antibody anti-CD46 monoclonal antibody | CD46 | Phase 1 | Prostate Cancer | Jul 2027 |
Prostate Cancer (2) Multiple Myeloma (1) Metastatic Castration-resistant Prostate Cancer (1) Metastatic Castration-Resistant Prostate Cancer (1)
mixed (2), small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.